Skip to main content
. Author manuscript; available in PMC: 2012 Nov 18.
Published in final edited form as: Sci Transl Med. 2011 Jul 6;3(90):90ra59. doi: 10.1126/scitranslmed.3002356

Fig. 1.

Fig. 1

Derivation and characterization of TKI-resistant cells. (A and B) PC-9 erlotinib-resistant cells (PC-9/ER) (panel A) and PC-9 BIBW-2992–resistant cells (PC-9/BR) (panel B) were derived after ~120 days of culture with increasing concentrations of drug. Growth inhibition assays show that these cells are resistant to respective TKIs compared to the parental cells. (C) Direct dideoxynucleotide sequencing chromatograms from EGFR exon 20 (ex20) show the presence of the T790M mutation (*ACG→ATG) in the PC-9/ER and PC-9/BR cells but not in parental cells. F, forward; R, reverse directions.